Global Immunology Leader Argenx to Participate in Fireside Chat at BofA Securities Health Care Conference

Argenx, a global immunology company dedicated to improving the lives of individuals with severe autoimmune diseases, is set to participate in a fireside chat at the BofA Securities 2024 Health Care Conference on May 14, 2024, at 10:00 AM PT in Las Vegas, NV. This event will feature members of the management team and a live webcast of the fireside chat will be available on the Investors section of the Argenx website at www.argenx.com/investors. A replay of the webcast will also be accessible on the website for approximately 90 days after the event.

Argenx has developed and commercialized the first approved neonatal Fc receptor (FcRn) blocker in multiple regions around the world through its Immunology Innovation Program (IIP). The company is currently evaluating efgartigimod in various serious autoimmune diseases and advancing several early-stage experimental medicines within its therapeutic franchises. For more information about Argenx, visit their website at www.argenx.com and follow them on social media platforms like LinkedIn, Twitter, Instagram, Facebook, and YouTube.

For media inquiries, please contact Ben Petok at bpetok@argenx.com. For investor-related questions, reach out to Alexandra Roy (US) at aroy@argenx.com or Lynn Elton (EU) at lelton@argenx.com